Psychedelic Drugs Market Report 2026

Psychedelic Drugs Market Overview

• Psychedelic Drugs market size has reached to $6.33 billion in 2025 • Expected to grow to $13.67 billion in 2030 at a compound annual growth rate (CAGR) of 16.7% • Growth Driver: Surging Cases Of Mental Illness To Drive Market Growth • Market Trend: Advancements In Therapeutic Psilocybin Formulations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Psychedelic Drugs Market?

Psychedelic drug refers to a group of psychoactive drugs that alter perception, mood, and thought processes. All the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. These include chemicals such as Lysergic acid diethylamide (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions. The main types of psychedelic drugs are lysergic acid diethylamide, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Psychedelic Drugs Market Growth Forecast?

The psychedelic drugs market size is expected to see rapid growth in the next few years. It will grow to $13.67 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to regulatory approvals for medical use, growing psychiatrist adoption, expansion of indication pipeline, improved patient outcomes data, strategic partnerships between biotech and healthcare providers. Major trends in the forecast period include expansion of psychedelic-assisted therapy programs, increasing clinical trials for mental health indications, growing acceptance of alternative psychiatry treatments, regulatory pathway clarification for controlled substances, rising investment from venture capital and pharma players.

Global Psychedelic Drugs Market Segmentation

1) By Type: Lysergic Acid Diethylamide (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia 2) By Disease Indication: Depression, PTSD 3) By Origin: Natural, Synthetic 4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders 5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Lysergic Acid Diethylamide (LSD): LSD Tablets, LSD Liquid, LSD Blotters 2) By Ketamine: Ketamine Infusion, Ketamine Nasal Spray, Ketamine Injectable 3) By Phencyclidine (PCP): PCP Powder, PCP Tablets, PCP Liquid 4) By Gamma Hydroxybutyric Acid (GHB): GHB Liquid, GHB Powder, GHB Capsules 5) By Salvia: Salvia Extract, Salvia Dried Leaves, Salvia Tinctures

What Is The Driver Of The Psychedelic Drugs Market?

The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drugs market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in November 2023, according to the National Health Service, a UK-based government department, in 2023, approximately one in five individuals aged 8 to 25 years were estimated to have a probable mental disorder, affecting 20.3% of 8 to 16-year-olds, 23.3% of 17 to 19-year-olds, and 21.7% of 20 to 25-year-olds. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drugs industry.

Key Players In The Global Psychedelic Drugs Market

Major companies operating in the psychedelic drugs market are Atai Life Sciences, Cybin Inc., Mind Medicine Inc., Compass Pathways, Seelos Therapeutics, Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation, Beckley Psytech, Awakn Life Sciences, Psygen Industries, Enveric Biosciences, Filament Health, Tactogen, Bexson Biomedical, BetterLife Pharma, Clairvoyant Therapeutics, Universal Ibogaine

Global Psychedelic Drugs Market Trends and Insights

Major companies operating in the psychedelic drugs market are focusing on developing innovative solutions such as pharmaceutical-grade psilocybin formulations to enhance therapeutic efficacy, ensure safety, and expand treatment options for mental health disorders. Grade psilocybin formulation refers to psilocybin produced and standardized to pharmaceutical-grade quality, ensuring consistent purity, potency, and safety for therapeutic use. For instance, in September 2025, Optimi Health, an Australia-based psychedelic therapeutics company, launched its natural psilocybin capsules in Australia for the treatment of TRD. With this launch, Optimi Health aims to provide a clinically supported treatment option for patients, expand its presence in the Australian mental health market, and accelerate the adoption of psychedelic-assisted therapies.

What Are Latest Mergers And Acquisitions In The Psychedelic Drugs Market?

In October 2023, Cybin Inc., a Canada-based psychedelic therapeutics company, completed the acquisition of Small Pharma Inc., for an undisclosed amount. With this acquisition, Cybin aims to create an international clinical-stage leader in novel psychedelic therapeutics, expand its pipeline of psilocybin-based treatments, accelerate clinical development, and enhance its research and commercialization capabilities. Small Pharma Inc. is a UK-based clinical-stage biotechnology company focused on developing innovative psychedelic therapies for mental health disorders.

Regional Insights

North America was the largest region in the psychedelic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Psychedelic Drugs Market?

The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Psychedelic Drugs Market Report 2026?

The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.